Why Ironwood Pharmaceuticals (IRWD) is a Top Momentum Stock for the Long-Term

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market strategies, including daily updates, research reports, and stock screens [1] - The Zacks Style Scores are designed to help investors identify stocks with the highest potential to outperform the market within a 30-day timeframe [2] Zacks Style Scores Overview - The Style Scores consist of four categories: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] - Value Score emphasizes finding undervalued stocks based on financial ratios [3] - Growth Score assesses a company's financial health and future growth potential [4] - Momentum Score identifies stocks with favorable price trends and earnings outlooks [5] - VGM Score combines the three Style Scores to highlight stocks with attractive value, growth, and momentum [6] Zacks Rank and Performance - The Zacks Rank is a proprietary model that utilizes earnings estimate revisions to guide investors in stock selection [7] - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +23.81% since 1988, significantly outperforming the S&P 500 [8] - There are over 800 stocks rated 1 or 2, making it essential for investors to use Style Scores to narrow down choices [9] Stock Example: Ironwood Pharmaceuticals - Ironwood Pharmaceuticals (IRWD) is currently rated 1 (Strong Buy) with a VGM Score of A, making it a strong candidate for investment [11] - The stock has a Momentum Style Score of A, with a price increase of 15.6% over the past four weeks [11] - Analysts have revised IRWD's earnings estimate upwards, with the Zacks Consensus Estimate increasing by $0.03 to $0.16 per share, and the company has an average earnings surprise of +115.6% [12]